PreferredStockChannel

Slideshow Preferred Stock Offerings

By Preferred Stock Channel Staff, updated Sat, December 4, 3:18 AM

Slide #181. Fortress Biotech, Inc. Preferred Stock Offering

Company: Fortress Biotech, Inc. (NASDAQ:FBIO)
Date announced: 11/1/2017
Shares Offered: 1,000,000
Date of Pricing: 11/7/2017
Price Per Share: $25.00
Preferred Stock Offering Details: Fortress Biotech, Inc. (Nasdaq:FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that it intends to offer and sell shares of its Series A Cumulative Redeemable Perpetual Preferred Stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Fortress. In addition, Fortress intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares offered in the public offering. The Series A Preferred Stock has received an "A-" investment-grade rating from Egan-Jones Rating Co., an independent, unaffiliated rating agency. -updated 11/7- Fortress Biotech, Inc. (Nasdaq:FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that it has priced an underwritten public offering of one million shares of its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock at a price of $25.00 per share, with expected gross proceeds to Fortress of $25 million. In addition, Fortress has granted the underwriters a 30-day option to purchase up to 150,000 additional shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 14, 2017, subject to customary closing conditions. The Series A Preferred Stock has received an "A-" investment-grade rating from Egan-Jones Rating Co., an independent, unaffiliated rating agency.

Fortress Biotech is a biopharmaceutical company focused on acquiring, developing and commercializing pharmaceutical and biotechnology products and product candidates. Through its partner company, Co. markets the following dermatology products: Ximino®, which is a tetracycline-class drug indicated to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox®, which is a tetracycline-class drug indicated as adjunctive therapy for severe acne; and Ceracade®, which is a steroid-free, ceramide-dominant formulation used to treat dry skin conditions and to manage and relieve the burning and itching associated with various types of dermatitis and radiation dermatitis.

Preferred: FBIOP


Open the FBIO Page at Preferred Stock Channel »

Name: 
Fortress Biotech Inc
Website: 
www.fortressbiotech.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding FBIO: 
14 (see which ones)
Total Market Value Held by ETFs: 
$14,710,460.85
Total Market Capitalization: 
$284,000,000
% of Market Cap. Held by ETFs: 
5.18%
 

Open the FBIO Page at Preferred Stock Channel (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree FBIO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Strong Buy (4.00 out of 4)
90th percentile
(ranked higher than approx. 90% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com
Top Ten Highest Yielding Preferred Stocks
Feel-Good Income: Socially Responsible Preferreds
Dividend Channel's 25 S.A.F.E. Dividend Stocks
Increasing Payments For Decades

Safer than S.A.F.E: Preferreds of Dividend Channel's
S.A.F.E. Dividend Stocks

Recent Preferred Stock Offerings
Preferred Stocks of Dow Components
Preferred Stocks of S&P 500 Components
Preferred Stocks By Industry
Preferred Stocks Where Insiders Are Buying The Common
High Yield Preferred Stocks
Preferreds Trading At Premiums To Liquidation Preference
Preferreds Trading At Discounts To Liquidation Preference
The Top 10 DividendRank'ed U.S. Stocks
The Top 10 DividendRank'ed Canadian Stocks
Top 25 Broker Analyst Picks of the S&P 500
Stock market game

Preferred Stock Offerings - Slide 181 of 573 | www.PreferredStockChannel.com

Copyright © 2010 - 2021, All Rights Reserved Nothing in Preferred Stock Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact Preferred Stock Channel; Meet Our Editorial Staff.